An Introduction to DKFZ

Otmar D. Wiestler Deutsches Krebsforschungszentrum, Heidelberg

Page 1 DKFZ Locations on Campus Cancer Research @ DKFZ

• Established in 1964

• National research center

• Helmholtz association

• Location on Heidelberg biomedical campus

• Team of 3000 members

• Funding from BMBF & BW

• Coordination of national & international activities

Helmholtz International Graduate School for Cancer Research

• High quality, comprehensive, structured and interdisciplinary graduate training in cancer research

• Vivid interaction with international partners (Karolinska, MDACC, WIS)

• Cooperation with Universites and Helmholtz centers

450 graduate students

National Reference Center for Cancer Information New and expanding research fields

Cancer genome Epigenetics, Small regulatory RNAs Systems biology of cancer & modelling Angiogenesis Cancer stem cells Metabolic dysfunction & cancer Cancer immunotherapies Neurooncology High field MRI, molecular imaging Particle therapy, radiation biology Epidemiology, early detection & prevention Stem cells & Cancer

• Cancers originate from somatic stem or progenitor cells

• Cancer cells with stem cell properties control tumor growth and biology

• Cancer stem cells serve as a reservoir for tumor progression and recurrence DKFZ Cancer Stem Cell Program

Joint activity with the Dietmar-Hopp-Foundation

Three HI-STEM Junior Research Groups Marieke Essers Michael Milsom Christoph Rösli Cancer Genome Consortium

• High number of genomic alterations in cancer cells

• Striking inter-individual variability

• Mutation analysis as basis for individualized treatment

• International Cancer Genome Consortium Isocitrate dehydrogenases

IDH1 IDH2 cytosolic mitochondrial NADP+ specific NADP+ specific

IDH3A / IDH3B / IDH3G

Mitochondrial NAD+ specific Andreas von Deimling 1

0.500

0.450

untr. 0.400 wt H 0.350 E Q

0.300 S C V 0.250 L G 0.200 GFP

0.150

0.100

0.050

0.000 0 5 10 15 20 25 30 35 40 45 wt mut % mut

IDH1 Pilocytic astrocytoma WHO grade I (PA I) 41 40 1 2% Subependymal giant cell astrocytoma WHO grade I (SEGA I) 12 12 0 0% Pleomorphic xanthoastrocytoma WHO grade II (PXA II) 7 7 0 0% 685 Astrocytoma WHO grade II (A II) 46 13 34 74% Anaplastic astrocytoma WHO grade III (A III) 47 18 29 62% CNS tumors Primary Glioblastoma WHO grade IV (prGBM) 99 92 7 7% Secondary glioblastoma WHO grade IV (secGBM) 8 1 7 88% Giant cell glioblastoma WHO grade IV (gcGBM) 8 6 2 25% Pediatric Glioblastoma WHO grade IV (pedGBM) 14 13 1 7% Gliosarcoma WHO grade IV (GS) 5 5 0 - Oligodendroglioma WHO grade II (O II) 51 15 36 71% Anaplastic oligodendroglioma WHO grade III (O III) 54 18 36 67% Oligoastrocytoma WHO grade II (OA II) 46 10 36 78% Anaplastic oligoastrocytoma WHO grade III (OA III) 37 8 29 78% Myxopapillary ependymoma WHO grade I (E myx I) 6 5 0 - Ependymoma WHO grade II (E II) 15 15 0 0% Anaplastic ependymoma WHO grade III (E III) 10 10 0 0% Medulloblastoma WHO grade IV (MB IV) 58 58 0 0% Primitive neuroectodermal tumor WHO grade IV (PNET) 9 6 3 33 % Schwannoma WHO grade I (S I) 17 17 0 0% Meningioma WHO grade I (M I) 38 38 0 0% Atypical meningioma WHO grade II (M II) 17 17 0 0% Anaplastic meningioma WHO grade III (M III) 17 17 0 0% Pituitary adenoma WHO grade I (PIAD) 23 23 0 0%

Cancer Genome Research

PED-NET Additional projects : Early onset prostate cancer Malignant lymphoma Cancer Genome Research

International Cancer Genome Consortium DKFZ ultradeep sequencing facility Data storage facility BioQuant & DKFZ 6 petabyte capacity Cancer genome sequencing in a diagnostic setting

Peter Lichter, Roland Eils Cancer genome sequencing

• RNA / exome sequencing • Genome sequencing tumors Prostate cancer High capacity ultradeep Pancreatic cancer sequencing facility at DKFZ • Applied bioinformatics • Vector insertion analysis

NCT Outpatient Cancer Genome Treatment Unit Research Group

PAGE 18 Strategies for Cancer Immunotherapy

T Cell Therapy

IMMUNOTHERAPY

Breaking Leukemia Hepato- Vaccination Apoptosis and cellular Melanoma Strategies Resistance Lymphoma Carcinoma

IMMUNOMONITORING

Antibody Therapy APG101 : First in man

• DKFZ spin off Extracellular domain of the human CD95 receptor • First CD95 ligand blocker in clinical development

• Specific inhibitor of CD95L mediated activation Fc-domain of human IgG • Well tolerated in phase I

CD95 • Phase II trial in GBM ongoing Ligand CD95 • Cell FAD PI3 Additional clinical targets D K (pancreas, MDS, GvHD) Caspases AKT/NFkB 8/3

Apoptosis Survival Migration PREPARATION OF A PHASE I/II CLINICAL TRIAL FOR ONCO- LYTIC VIROTHERAPY OF GLIOBLASTOMA MULTIFORME

Jean ROMMELAIRE & Karsten GELETNEKY, DKFZ & University of Heidelberg

Why glioblastoma? Preclinical proof of concept H-1 PV days p.i. (rat autologous intracranial glioma) • most common primary • complete recovery from symptomatic brain tumour disease, without signs of toxic or (2-3 % of all human inflamatory side effects 0 malignancies) • long term survival without tumour • dismal relapse prognosis 1 Survival 3 (< 5% long term rate: H-1 survivors) 0.5

control 7 0 10 20 30 from: Kleihues, P., days after implantation Kiessling, M., Wiestler, O.D. (2004)

Trial •Target: non-resectable, progressing, malignant non-multifocal glioma (grade IV) •Design: single center, non-randomized, i.t. dose escalation study •Objective: assessment of safety and biodistribution of H-1 PV, evidence for antitumoral activity 7T MRI : a new dimension in medical imaging Glioblastoma multiforme

7 T: TSE T2 7 T: MR Angiography 7 T MRI : A new dimension in MR imaging Image guided radiation therapy

• Artiste : CT-LINAC for IGRT

• MR-LINAC for IGRT

• Continuous real time adaptation of the radiation beam Heidelberg Ion-Beam Therapy Center A new era in radiooncology

Enrolling patients since Nov. 2009

• Image-guided radiotherapy

• Clinical targets for particle therapy

• Ions vs. protons and photons

• Radiooncology and biologicals

• Applied radiobiology (modulators of RT) Prevention is better than cure ! Vaccination against oncogenic human papilloma viruses : A milestone in preventive oncology

Nobel prize for Harald zur Hausen 2008 Model projects in preventive oncology

• Early detection of colorectal cancer • Colorectal cancer in 1st degree relatives • Metabolic syndrome & cancer • Physical activity and cancer • Familial cancers (BRCA, HNPCC) • National cohort study National Cohort

• 200,000 adults (20-70 years) North west: Kiel • Multiple regions in n=30,000 Lübeck Neubrandenburg Hamburg • Close cooperation between Helmholtz centers and (MDC) Hannover Braunschweig Brandenburg Universities (HZI) Münster • 8 National recruitment Essen Bochum Halle centers Düsseldorf Bonn • Defined subcohorts (DZNE) • Close collaboration

with universities Saarland Mannheim Heidelberg Regensburg • Training pograms (DKFZ) Augsburg (HMGU) Freiburg Projected age distribution

Joint activities & structures

Clinical Cooperation Immunology Units (SFB 938, Alliance)

Junior Research Stem Cell Research Groups (SFB 873, HI-STEM)

Funding for Neurooncology Tandem Projects (NGFN, ICGC)

Funding for MD Imaging Students & Rotations

Heidelberg Ion Radiooncology Training Activities Therapy (HIT) (HIRO)

Translational research requires national efforts

• Translational cancer research facing grand challenges

• Excellent research in German laboratories

• Individual sites not sufficiently competitive

• Lack of coordinated efforts and critical mass

• Translational research requires novel alliances between the best partners

Translational research programs Translational research platforms Consortium School of Oncology

Provide Education in Clinical Oncology, combining training on interdisciplinary cancer diagnosis, HSO patient care and translational cancer research

Facilitate and improve multidisciplinary,scientific and clinical interactions between laboratory-based HSO scientists and clinician scientists

Establish training programs in translational research for physicians, physician scientists and HSO life science experts

Offer continued medical education for center physicians, GPs and private practitioners HSO in oncology International relationships

30 yrs. DKFZ & MOST / Israel joint funding program INSERM unit and DKFZ - Canceropolé consortium Helmholtz units at French INSERM sites DKFZ & MD Anderson Cancer Center SI agreement DKFZ & NCI exchange program DKFZ & Karolinska DKFZ & NCC Tokyo DKFZ & Clinica d‘Alemana (Santiago de Chile) DKFZ & Weizmann Institute joint graduate school Programs with partners from China, Poland, Tanzania German-Israeli Helmholtz Research School in Cancer Biology

DKFZ & NCI, Washington February 2010

DKFZ & Siemens Health Care A strong R&D alliance

• Integrated Diagnosis & Therapy (IDTZ) • High field MRI (7T) for oncology • Molecular imaging • IT platform Public Private Partnerships

• Strategic alliance DKFZ & Siemens • Strategic alliance DKFZ & Bayer Schering Pharma • Hi-STEM & BioRN • Spin outs

Apogenix Progen mtm Affimed Oncology of the Future

• Molecular diagnosis & stratification

• Targeted treatments

• Innovative radiooncology

• Intelligent combinations

• Individualized treatment

• Cancer as chronic disease

• Cancer prevention Welcome to the German Cancer Research Center ! Welcome at the DKFZ !